Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  The Lancet

• Publication date

  1990-09-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0140-6736(90)92205-VPMID 1975893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autoantibodies to myeloid lysosomal enzymes: new clues to vasculitis and glomerulonephritis. A hypothesis based on humoral immune mechanisms.

  1990cited by this paper
• Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme

  1990cited by this paper
• Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.

  1990cited by this paper
• Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis.

  1990cited by this paper
• The role of the c-ANCA antigen in the pathogenesis of Wegener's granulomatosis. A hypothesis based on both humoral and cellular mechanisms.

  1990cited by this paper
• Wegener9s granulomatosis autoantigen is a novel neutrophil serine proteinase [see comments]

  1989cited by this paper
• Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase.

  1989cited by this paper
• Comment on the article by DeRemee.

  1989cited by this paper
• Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis.

  1989cited by this paper
• Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

  1989cited by this paper
• Association between active Wegener's granulomatosis and anticytoplasmic antibodies.

  1989cited by this paper
• Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis.

  1989cited by this paper
• Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

  1989cited by this paper
• Infectious complications of cyclophosphamide treatment for vasculitis.

  1989cited by this paper
• Anti-neutrophil cytoplasm antibodies 1988.

  1988cited by this paper
• Anti-neutrophil cytoplasm antibodies 1988.

  1988cited by this paper
• Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis.

  1988cited by this paper
• Sulfamethoxazole-trimethoprim therapy for Wegener's granulomatosis.

  1988cited by this paper
• Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis.

  1988cited by this paper
• The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision?

  1988cited by this paper
• Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis.

  1987cited by this paper
• Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis.

  1985cited by this paper
• Wegener's granulomatosis: observations on treatment with antimicrobial agents.

  1985cited by this paper
• Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration.

  1984cited by this paper
• Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

  1983cited by this paper
• Wegener's granulomatosis: observations on 18 patients with severe renal disease.

  1983cited by this paper
• Relapses in Wegener's granulomatosis: the role of infection.

  1980cited by this paper
• The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations.

  1978cited by this paper
• Wegener's granulomatosis. Long-term followup of patients treated with cyclophosphamide.

  1975cited by this paper

• Seasonal variation in incidence and relapse of granulomatosis with polyangiitis: A retrospective cohort study from Central Anatolia

  2025cites this paper
• Biomarkers in ANCA associated vasculitis: clinical utility, pitfalls and their role in the outcomes assessment

  2025cites this paper
• Recurrent spontaneous renal hemorrhage in end-stage renal disease with ANCA-associated vasculitis: a case-based review

  2025cites this paper
• EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

  2023cites this paper
• Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial

  2023cites this paper
• Old known and possible new biomarkers of ANCA-associated vasculitis.

  2022cites this paper
• Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement

  2022cites this paper
• Introduction on translational autoimmunity: From bench to bedside

  2022cites this paper
• Clinical patterns and risk factors in scleritis: a multicentric study in Colombia

  2022cites this paper
• Do Relapses Follow ANCA Rises? A Systematic Review and Meta-Analysis on the Value of Serial ANCA Level Evaluation

  2022cites this paper
• Anti-neutrophil cytoplasmic antibody patterns can predict clinical relapse in ANCA-associated vasculitis: overall population and subgroups.

  2022cites this paper
• Association between kinetic of Anti-Neutrophil Cytoplasmic Antibody (ANCA), renal survival and relapse risk in ANCA-glomerulonephritis.

  2022cites this paper
• Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis

  2020cites this paper
• Serological testing in small vessel vasculitis.

  2020cites this paper
• Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials.

  2020cites this paper
• Antineutrophil cytoplasmic antibodies (ANCA) – their role in pathogenesis, diagnosis, and treatment monitoring of ANCA-associated vasculitis

  2020cites this paper
• Association between sinusitis and relapse and changes in the myeloperoxidase–antineutrophil cytoplasmic antibody in microscopic polyangiitis

  2020cites this paper
• Interventions for renal vasculitis in adults.

  2020cites this paper
• Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis

  2019influential citation
• Atteintes rénales des vascularites à anticorps anticytoplasme des neutrophiles

  2019cites this paper
• Remission maintenance in ANCA-associated vasculitis: does one size fit all?

  2019cites this paper
• Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a “Personalized Medicine Approach” in ANCA-Associated Vasculitis

  2019cites this paper
• Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

  2018cites this paper
• Chapter 3 Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener ' s granulomatosis

  2018cites this paper
• Chapter 4 Image analysis ; a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener ’ s Granulomatosis

  2018cites this paper
• Predicting relapses in ANCA associated vasculitis

  2018cites this paper
• Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement

  2017influential citation
• Testing anti-neutrophil cytoplasmic antibodies (ANCA): analysis of the European EASI survey on the daily practice of the French laboratories.

  2017cites this paper
• Cardiac Involvement in Systemic Vasculitis

  2017cites this paper
• Allergy and autoimmunity: Molecular diagnostics, therapy, and presumable pathogenesis

  2017cites this paper
• vasculitis: is the glass half full or half empty? Predictive value of antineutrophil cytoplasmic antibodies in small-vessel

  2017cites this paper
• ntineutrophil Cytoplasm Autoantibodies : Usefulness in Rheumatology

  2017cites this paper
• Maintaining remission in patients with granulomatosis with polyangiitis or microscopic polyangiitis: the role of ANCA

  2017influential citation
• The avidity of PR3‐ANCA in patients with granulomatosis with polyangiitis during follow‐up

  2016cites this paper
• Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides.

  2016cites this paper
• Improving patient outcomes in systemic vasculitis

  2016cites this paper
• Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3

  2016cites this paper
• Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis.

  2016cites this paper
• Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse

  2015cites this paper
• Infections and Autoimmune Renal Diseases

  2015cites this paper
• The Renaissance of Antineutrophil Cytoplasmic Antibodies as a Predictor of Relapse: Ippon for Japan

  2015cites this paper
• Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?

  2015cites this paper
• Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis – still of value for our patients?

  2015influential citation
• Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long?

  2015influential citation
• Interventions for renal vasculitis in adults.

  2015cites this paper
• ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease.

  2015cites this paper
• UNIVERSITE DE LAUSANNE-FACULTE DE BIOLOGIE ET MEDECINE DEPARTEMENT DE MEDECINE Service d'immunologie et d'allergie Chef de Service : Professeur Giuseppe Pantaleo PREDICTIVE VALUE OF ANTl-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN SMALL VESSEL VASCULITIS

  2014cites this paper
• Clinical immunology--autoimmunity in the Netherlands.

  2014cites this paper
• Autoantibodies in anti-neutrophil cytoplasm antibody-associated vasculitis.

  2014cites this paper
• Role of the clinical immunology laboratory in disease monitoring

  2013cites this paper
• C-ANCA/Proteinase 3–Positive Colitis in Children: A Distinctive Form of Inflammatory Bowel Disease or Vasculitis With Colitis as Initial Presentation?

  2013cites this paper
• L27. Antibodies versus phenotypes: a clinician's view.

  2013cites this paper
• Antineutrophil cytoplasm autoantibodies: usefulness in rheumatology.

  2012cites this paper
• Treat-to-target in vasculitis: is this a sensible approach?

  2012cites this paper
• Antineutrophil Cytoplasmic Autoantibodies: How Are They Detected and What Is Their Use for Diagnosis, Classification and Follow-up?

  2012cites this paper
• Epidemiology, genetic differences and clinical outcomes of antineutrophil cytoplasmic autoantibody associated systemic vasculitis

  2012cites this paper
• Autoantibodies and Vascular Inflammation

  2012cites this paper
• Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

  2012cites this paper
• Antineutrophil Cytoplasm Autoantibodies: Usefulness in Rheumatology☆

  2012cites this paper
• Autoanticorps anticytoplasme des polynucléaires neutrophiles (ANCA) et vascularites : diagnostic et physiopathologie

  2012cites this paper
• [Current trends in classification and treatment of systemic vasculitis associated with anti-neutrophilic cytoplasmic antibodies: results of 2011].

  2012cites this paper
• Current modalities in the diagnosis of pulmonary vasculitis.

  2012cites this paper
• Autoanticorps anticytoplasme des polynucléaires neutrophiles (ANCA) : cibles antigéniques, méthodes diagnostiques

  2012cites this paper
• WEGENER'S GRANULOMATOSIS IN FINLAND IN 1981-2000

  2011cites this paper
• Rituximab in ANCA-associated vasculitis: a revolution?

  2011cites this paper
• Rituximab in ANCA-associated vasculitis: a revolution?

  2011cites this paper
• Pathogenesis of ANCA-associated vasculitides

  2011cites this paper
• New pathophysiological insights and treatment of ANCA-associated vasculitis.

  2011cites this paper
• A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy.

  2011cites this paper
• Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's).

  2011cites this paper
• Pathogenesis of ANCA-Associated Vasculitis, an Update

  2011cites this paper
• ANCA Associated Vasculitis

  2010cites this paper
• Management of ANCA-associated vasculitis: Current trends and future prospects

  2010cites this paper
• Recurrent pauci-immune necrotizing crescentic glomerulonephritis in a kidney transplant patient.

  2010cites this paper
• Drug-induced and Iatrogenic Respiratory Disease

  2010cites this paper
• Clinical Outcome and Prognosis of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Japan

  2010cites this paper
• Outcome measures in ANCA-associated vasculitis.

  2010cites this paper
• Reduction of MPO-ANCA epitopes in SCG/Kj mice by 15-deoxyspergualin treatment restricted by IgG2b associated with crescentic glomerulonephritis.

  2010cites this paper
• Pauci-immune necrotizing glomerulonephritis.

  2010cites this paper
• Predictors of Damage and Survival in Patients with Wegener’s Granulomatosis: Analysis of 50 Patients

  2010cites this paper
• The role of endothelial progenitor cells in the pathogenesis of anti - neutrophil cytoplasmatic antibody - associated vasculitis

  2010cites this paper
• An approach to the diagnosis and management of systemic vasculitis

  2010cites this paper
• Clinical management and treatment of vasculitis

  2009cites this paper
• ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.

  2009cites this paper
• 維持透析導入後も18年間MPO-ANCA高値が持続し，肺胞出血で再燃した顕微鏡的多発血管炎の1例

  2009cites this paper
• ANCA-associated vasculitis: pathogenesis, novel markers of the disease and emerging therapies.

  2009cites this paper
• T-Lymphocytes and Disease Mechanisms in Wegener’s Granulomatosis

  2009cites this paper
• Pregnancy complicating Wegener's granulomatosis

  2009cites this paper
• Review article: Progress of treatment in ANCA‐associated vasculitis

  2009cites this paper
• EUROPLUS ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis.

  2009cites this paper
• CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis

  2008cites this paper
• Pathogenesis of PR3-ANCA associated vasculitis.

  2008cites this paper
• Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides

  2008cites this paper
• Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis

  2008cites this paper
• Wegener’s granulomatosis: an update on diagnosis and therapy

  2008cites this paper
• A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis

  2008cites this paper
• Assessment of systemic vasculitis.

  2008cites this paper
• Antineutrophil Cytoplasmic Autoantibodies: How Should the Biologist Manage Them?

  2008cites this paper
• ANCA-Associated Glomerulonephritis and Systemic Vasculitis in Kidney – A Pathologist ’ s Perspective

  2008cites this paper
• ANCA-associated vasculitis : factors involved in disease induction, survival and long-term complications

  2007cites this paper